Recurrent pericarditis (RP) has posed a therapeutic challenge, with treatments consisting of nonsteroidal anti-inflammatory drugs, corticosteroids, drug-modifying antirheumatic drugs (DMARDs) and in refractory cases, pericardiectomy. Many patients can experience unpredictable flares, with some developing corticosteroid dependence, reduced quality of life, and repeated hospitalizations. Over the years, there has been emerging insights and understanding of the autoinflammatory nature of the disease, and appreciation of the immunologic axis in the role of recurrence.
